Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Cencora moves billions of dollars in branded, generic, and specialty drugs—and how much it sets aside for opioid litigation—means combing through dense regulatory documents. Cencora SEC filings explained simply is what most investors search for when a new disclosure lands. Stock Titan solves that problem by turning every freshly posted exhibit, footnote, and schedule into plain-English insights within minutes.
Our platform reads each Cencora annual report 10-K simplified, compares segment margins, and highlights cash-flow drivers hidden in accounting tables. You’ll also receive instant alerts the moment a director files Cencora Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that clarify complex wording and accounting changes
- Real-time push notifications for new 10-K, 10-Q, 8-K, and Cencora insider trading Form 4 transactions
- Side-by-side visuals that streamline Cencora earnings report filing analysis
Whether you’re waiting for the next Cencora quarterly earnings report 10-Q filing, researching Cencora executive stock transactions Form 4, or need Cencora 8-K material events explained after an unexpected acquisition, everything is organized in one place. We even map the pages inside the Cencora proxy statement executive compensation section, so pay packages are only a click away. Stop downloading PDFs; start understanding Cencora SEC documents with AI that surfaces the metrics that matter.
Cencora (NYSE:COR) filed a Form 4 reporting insider transactions by Executive Chairman Steven H. Collis on 24 June 2025.
Collis exercised 12,579 stock options at an exercise price of $86.09 (code M) and sold 14,579 common shares at an average price of $292.62 (code S) under a pre-arranged Rule 10b5-1 trading plan adopted 25 Nov 2024. The sale is valued at roughly $4.3 million.
Following the transactions he directly owns 311,912.665 shares of common stock and retains 113,206 outstanding options. The disposition represents about 4.7 % of his prior direct holdings, yet he continues to hold a substantial equity stake.
Cencora, Inc. (Form 144) – A notice of proposed insider sale has been filed for 14,579 common shares with an estimated aggregate market value of $4,266,106.98. The sale is expected to be executed on 06/24/2025 through Fidelity Brokerage Services on the NYSE.
The filing discloses that Cencora has 193,823,487 shares outstanding; the planned transaction therefore represents roughly 0.0075 % of the company’s total shares, indicating an immaterial effect on share count but providing insight into insider behavior.
Acquisition background:
- 2,000 shares acquired via restricted-stock vesting on 09/30/2023 (compensation).
- 12,579 shares acquired via option exercise dated 06/24/2025 (cash payment).
Recent insider activity (past three months):
- 03/25/2025 – 14,578 shares sold for $3,928,916.78
- 04/22/2025 – 14,579 shares sold for $4,108,507.99
- 05/20/2025 – 14,578 shares sold for $4,283,599.52
No relationship to the issuer is specified in the excerpt, and no Rule 10b5-1 plan adoption date is provided. The filer certifies that no undisclosed material adverse information is known at the time of filing.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
